Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.1.3 (
ATPase
)
65,361
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In addition to being a master regulator of cell cycle progression, E2F1 regulates other associated biological processes, including growth and malignancy. Here, we uncover a regulatory network linking E2F1 to lysosomal trafficking and mTORC1 signaling that involves v-
ATPase
regulation. By immunofluorescence and time-lapse microscopy we found that E2F1 induces the movement of lysosomes to the cell periphery, and that this process is essential for E2F1-induced mTORC1 activation and repression of autophagy. Gain- and loss-of-function experiments reveal that E2F1 regulates v-
ATPase
activity and inhibition of v-
ATPase
activity repressed E2F1-induced lysosomal trafficking and mTORC1 activation. Immunoprecipitation experiments demonstrate that E2F1 induces the recruitment of v-
ATPase
to lysosomal RagB GTPase, suggesting that E2F1 regulates v-
ATPase
activity by enhancing the association of V0 and V1 v-
ATPase
complex. Analysis of v-
ATPase
subunit expression identified B subunit of V0 complex,
ATP6V0B
, as a transcriptional target of E2F1. Importantly,
ATP6V0B
ectopic-expression increased v-
ATPase
and mTORC1 activity, consistent with
ATP6V0B
being responsible for mediating the effects of E2F1 on both responses. Our findings on lysosomal trafficking, mTORC1 activation and autophagy suppression suggest that pharmacological intervention at the level of v-
ATPase
may be an efficacious avenue for the treatment of metastatic processes in tumors overexpressing E2F1.
...
PMID:V-ATPase: a master effector of E2F1-mediated lysosomal trafficking, mTORC1 activation and autophagy. 2635 14